TY - JOUR
T1 - Human T cell lymphotropic virus-associated leukemia/lymphoma
AU - Ratner, Lee
PY - 2005/9
Y1 - 2005/9
N2 - Purpose of review: This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options. Recent findings: New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition. Summary: Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor κB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor κB activation.
AB - Purpose of review: This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options. Recent findings: New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition. Summary: Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor κB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor κB activation.
KW - Human T cell leukemia/lymphoma
KW - Lymphoma
KW - T cell leukemia/lymphoma
UR - http://www.scopus.com/inward/record.url?scp=24044505750&partnerID=8YFLogxK
U2 - 10.1097/01.cco.0000174037.84903.fb
DO - 10.1097/01.cco.0000174037.84903.fb
M3 - Review article
C2 - 16093798
AN - SCOPUS:24044505750
SN - 1040-8746
VL - 17
SP - 469
EP - 473
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
IS - 5
ER -